Hold Rating on Allakos Amid Clinical and Financial Setbacks With AK006
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Allakos Downgraded to Neutral From Overweight at Piper Sandler
JMP Securities Downgrades Allakos(ALLK.US) to Hold Rating
JMP Securities Initiates Allakos(ALLK.US) With Buy Rating, Announces Target Price $3
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
Promising Potential of Allakos's AK006 Drives Buy Rating Amidst Market Interest in Chronic Spontaneous Urticaria
A Quick Look at Today's Ratings for Allakos(ALLK.US), With a Forecast Between $1 to $7
Cautious Hold Rating for Allakos Amid Uncertain Clinical and Financial Outlook
Piper Sandler Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Allakos(ALLK.US) With Sell Rating, Maintains Target Price $1
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Allakos (ALLK) Gets a Hold From TD Cowen
Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
LifeSci Capital Maintains Allakos(ALLK.US) With Hold Rating
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3